B cells in chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL) differ from normal B cells in that they often have higher levels of ongoing BCR or other signaling pathway activity. This evidence concerns the gene BCR and mantle cell lymphoma.